SIRT1 and SIRT2 have emerged as promising targets for therapeutic interventions in various diseases associated with gut dysbiosis, including cancer, neurodegenerative disorders, and metabolic conditions [6,146,224]. The gene discussed is SIRT2; the disease is cancer.